Heterocyclic Compounds

Matches 1 - 50 out of 30,805	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/096624A1	FUMARATE, TARTRATE, MALATE, AND CITRATE SALTS OF AN EGFR INHIBITOR The present application provides salts and crystalline forms, and polymorphic crystalline forms of (R)-N-(2-(4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl)-5-( (6-(3-(3,5-difluorophenyl)isoxazolidin-2-yl)pyrimidin-4-yl)a mino)-4-methoxyp...
WO/2024/097848A1	MALONATE AND GLYCOLATE SALTS OF AN EGFR INHIBITOR The present application provides salts and crystalline forms, and polymorphic crystalline forms of (R)-N-(2-(4-(4-cyclopropylpiperazin-l-yl)piperidin-l-yl)-5-( (6-(3-(3,5- difluorophenyl)isoxazolidin-2-yl)pyrimidin-4-yl)amino)-4-met hoxy...
WO/2024/094827A1	CARBONIC ANHYDRASE IX LIGANDS FOR TARGETED DELIVERY APPLICATIONS The present invention relates to protein ligands against Carbonic Anhydrase IX (CAIX) as target of biomedical relevance. In particular, the highly specific ligands may be able to exclusively interact with antigens expressed on the surfac...
WO/2024/095127A1	SOLID STATE FORMS OF TIVOZANIB AND PROCESS FOR PREPARATION THEREOF The present disclosure encompasses solid state forms of Tivozanib, in embodiments crystalline polymorphs of Tivozanib, processes for preparation thereof, and pharmaceutical compositions thereof.
WO/2024/097172A1	ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...
WO/2024/095133A1	HETEROCYCLIC COMPOUND The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful a...
WO/2024/095012A1	PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS The invention relates to a compound of formula (Ia) and related aspects.
WO/2024/097897A1	LXR MODULATORS WITH BICYCLIC CORE MOIETY FOR TREATING DYSLIPIDEMIAS The present disclosure relates to novel compounds which are Liver X Receptor (LXR) modulators and to pharmaceutical compositions containing same. The present disclosure further relates to the use of said compounds in the prophylaxis and/...
WO/2024/093412A1	HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF A heterocyclic compound, a preparation method therefor, and an application thereof. The structural formula of the heterocyclic compound is as represented by formula I. The present compound has excellent bioavailability, can improve cereb...
WO/2024/097606A1	AHR AGONISTS The present disclosure relates to certain AHR agonist compounds, for example, having a general formula (I) to pharmaceutical compositions comprising the compounds, and to methods of using the compounds to treat immune-mediated diseases, ...
WO/2024/094156A1	AMINE COMPOUND AND USE THEREOF Provided is a compound represented by formula (I), or a stereoisomer thereof, an optical isomer thereof, a solvate thereof, an isotope derivative thereof, or a pharmaceutically acceptable salt thereof. The compound can be used as a ligan...
WO/2024/095003A1	NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: Formula (I) wherein Z, X, R1, R2, R4, R5, R6 and R7 are as defined in the specification, processes fo...
WO/2024/088237A1	LUMINESCENT MATERIAL, USE THEREOF, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
WO/2024/089008A1	HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING The present invention relates to compounds of formula (I) which are capable of activating STING (Stimulator of Interferon Genes). The present invention further relates to pharmaceutical compositions comprising at least a compound of form...
WO/2024/088922A1	HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, W, Y, Z, and R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods o...
WO/2024/088928A1	PROCESS FOR MANUFACTURING ALOGABAT The invention relates to novel processes for manufacturing 6-[[5-methyl-3-(6-methyl-3- pyridyl)isoxazol-4-yl]methoxy]-N-tetrahydropyran-4-yl-pyrida zine-3-carboxamide (1), or a pharmaceutically acceptable salt thereof. The processes acco...
WO/2024/091450A1	COMPOUNDS AND METHODS FOR TREATING CANCER The present disclosure relates to compounds for treating cancer. The compounds may prevent conversion of non-stem cancer cells into cancer-initiating cells caused by radiation treatment.
WO/2024/091024A1	COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
WO/2024/089582A1	SOLID STATE FORMS OF CILOFEXOR SALTS The present disclosure encompasses solid state forms of Cilofexor and salts thereof, in embodiments crystalline polymorphs of Cilofexor and salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
WO/2024/092039A1	COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Described herein, in part, are compounds that mediate the degradation of cyclin-dependent kinase 2 (CDK2), and are therefore useful in the treatment of various disorders, such as cancer.
WO/2024/091538A1	COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS The present disclosure relates to compounds of Formula (I) capable of modulating the activity of GPR52. The present disclosure further provides a process for the preparation of compounds of Formula (1) and methods of using compounds of F...
WO/2024/089421A1	TETRAZOLE DERIVATIVES The invention relates to compounds of formula (I) and related aspects.
WO/2024/089006A1	HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING The present invention relates to compounds of formula (I) which are capable of activating STING (Stimulator of Interferon Genes). The present invention further relates to pharmaceutical compositions comprising at least a compound of form...
WO/2024/083120A1	BENZYLAMINOQUINOLINE COMPOUND AND PREPARATION METHOD THEREFOR Disclosed in the present invention are a benzylaminoquinoline compound and a preparation method therefor. The present invention specifically relates to a compound represented by formula (II), a stereoisomer thereof and a pharmaceutically...
WO/2024/084447A2	AZETIDINYL BENZOXAZOLE COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS Compounds of formula (I) and an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3 and W, are as defined in the specification, are usef...
WO/2024/085224A1	CRYSTAL OF 2-(5-CYCLOPROPYL-3-(ETHYLSULFONYL)PYRIDIN-2-YL)-5-((TRIFLUOROMETHYL)SULFONYL)BEN ZO[D]OXAZOLE The present invention provides: a type 1 crystal of 2-(5-cyclopropyl-3-(ethylsulfonyl)pyridin-2-yl)-5-((trifluor omethyl)sulfonyl)benzo[d]oxazole represented by formula (1) and having diffraction peaks at 2θ of 14.3 ± 0.2°, 15.6 ± 0....
WO/2024/085695A1	NOVEL ALTIRATINIB DERIVATIVE, MANUFACTURING METHOD THEREFOR, AND COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION, ALLEVIATION, OR TREATMENT OF SKIN PIGMENTATION The present invention relates to a novel altiratinib derivative, a manufacturing method therefor, and a composition comprising same as an active ingredient for the prevention, alleviation, or treatment of skin pigmentation. The altiratin...
WO/2024/085225A1	CRYSTAL OF 2-(5-CYCLOPROPYL-3-(ETHYLSULFONYL)PYRIDIN-2-YL)-5-((TRIFLUOROMETHYL)SULFINYL)BEN ZO[D]OXAZOLE The present invention provides: a type 1 crystal of 2-(5-cyclopropyl-3-(ethylsulfonyl)pyridin-2-yl)-5-((trifluor omethyl)sulfinyl)benzo[d]oxazole represented by formula (1) and having diffraction peaks at 2θ of 8.5 ± 0.2°, 12.0 ± 0.2...
WO/2024/086296A1	COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K The present disclosure relates to the field of medicinal chemistry. In particular, the disclosure relates to a new class of small-molecules having a quinazoline structure or a quinoline structure according to Formula (I), wherein Ring A,...
WO/2024/084360A1	PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3 (PNPLA3) MODIFIERS The present invention relates to compounds of Formula A, and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such proce...
WO/2024/083177A1	AROMATIC ACETYLENE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF The present invention relates to an aromatic acetylene derivative, a preparation method therefor, and a medical use of a pharmaceutical composition containing the derivative. Specifically, the present invention relates to an aromatic ace...
WO/2024/083208A1	KIF18A PROTEIN INHIBITOR Provided in the present invention are a compound having a structure as represented by general formula (I); a deuterated substance, a stereoisomer or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing same...
WO/2024/084186A1	TREATMENT OF LEISHMANIASIS The presentation invention relates to compounds of formula (I) and pharmaceutical compositions thereof. The compounds may be used to treat an infection, such as a parasitic infection or a bacterial infection. In some embodiments, the com...
WO/2024/083237A1	SUBSTITUTED HETEROARYL BICYCLIC COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF The disclosure provides substituted heteroaryl bicyclic compounds as represented in Formula I and the use thereof, wherein, A1, A2, B1, B2, B3, ring Z, L, Cy1 and Cy2 are defined herein. The compounds of Formula I can be used to prevent ...
WO/2024/082470A1	ALPROSTADIL COUPLED NITRIC OXIDE DONOR MEDICINE AND USE THEREOF Provided are an alprostadil coupled nitric oxide donor compound or a pharmaceutically acceptable salt thereof. The medicine is decomposed into two active ingredients, namely alprostadil and nitric oxide, in vivo, the pharmacological acti...
WO/2024/083933A1	2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX 3CR1 There are disclosed certain 2,4,6-trisubstituted 1,3,5-triazine compounds of Formula (I), (I) and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are modulator...
WO/2024/083886A1	RNA-BINDING MOLECULES WITH A SMALL CORE SCAFFOLD (R-SCORE) AND USES THEREOF The present invention relates to novel RNA-binding azetidine compounds of general formula (I) and stereoisomeric forms, hydrates, solvates and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing s...
WO/2024/080655A1	COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING SAME, AND ELECTRONIC DEVICE HAVING SAME The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrod...
WO/2024/081893A1	SALT FORMS OF IRAK4 DEGRADERS The present disclosure relates generally to various salt forms and compositions thereof useful for the modulation of interleukin-1 receptor-associated kinase 4 ("IRAK4") via ubiquitination and/or degradation and uses of the same in the t...
WO/2024/079682A1	SULFOXIMINE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME The present invention relates to a sulfoximine compound having a novel structure, stereoisomers thereof or pharmaceutically acceptable salts thereof, and a use thereof for preventing or treating histone deacetylase-mediated diseases The ...
WO/2024/078569A1	AROMATIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF The present invention relates to an aromatic amide derivative, a preparation method therefor, and a use of a pharmaceutical composition comprising same in medicine. Specifically, the present invention relates to an aromatic amide derivat...
WO/2024/081904A1	METHODS FOR TREATING CANCER This disclosure provides compounds of Formula (I), Formula (II), Formula (III), and pharmaceutically acceptable salts of any of the foregoing, that inhibit PI3Kα. These compounds are useful for treating diseases such as cancer in a subj...
WO/2024/081927A1	COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION Provided herein are methods of improving (e.g., increasing) the production of viral particles (e.g., AAV) in mammalian cells (e.g., HEK293 or HEK293T cells) using selective HDAC6 inhibitors (e.g., compounds of Formula I, Formula II, or F...
WO/2024/078513A1	CONDENSED AZINES FOR TREATING CANCER The present disclose includes, among other things, compounds that treat or lessen the severity of a disorder, pharmaceutical compositions and methods of making and using the same.
WO/2024/076670A2	TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not l...
WO/2024/076891A1	POLO LIKE KINASE 4 INHIBITORS Disclosed herein are compounds of Formula (IV), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (IV...
WO/2024/076672A1	HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not l...
WO/2024/074611A1	PRMT5 INHIBITORS The present invention relates to compounds of formula (I) and salts, stereoisomers, atrop-isomers, rotamers, tautomers or N- oxides thereof that are useful as PRMT5 inhibitors. The present invention further relates to the compounds of fo...
WO/2024/077057A1	PHENYL OXY AMIDE KINASE INHIBITORS Compounds having activity as kinase inhibitors are provided. The compounds have Structure (I), or a stereoisomer, tautomer, or salt thereof, wherein, R1, R3, and m are as defined herein. Methods associated with preparation and use of suc...
WO/2024/075815A1	8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF The present invention addresses the problem of providing a cMLCK activator which can enhance myocardial contraction without the need to increase the concentration of calcium in cells. The problem is solved by a cMLCK activator comprising...

Matches 1 - 50 out of 30,805	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >